Benjamin R tenOever, PhD
- PROFESSOR | Microbiology
Research Topics:
Biodefense, Cellular Immunity, Infectious Disease, Influenza Virus, Interferon, Interferon Antagonists, Molecular Biology, Paramyxovirus, RNA, RNA Splicing & Processing, Signal Transduction, Transcription Factors, Vaccine Development, Viruses and Virologyhttp://www.mssm.edu/research/labs/tenoever-laboratory/projects-and-grants
Multi-Disciplinary Training Area
Microbiology [MIC]Education
PhD, McGill University
Harvard University
-
2017
Pew Innovator Award -
2015
Tocqueville Distinguished Chair Award -
2013
American Society of Virology Ann Palmenberg Award -
2012
Vilcek Award for Creative Promise -
2012
American Society of Gene and Cell Therapy Young Investigator Award -
2011
Cozzarelli Prize Recipient in Biomedical Sciences -
2011
Investigator in the Pathogenesis of Infectious Diseases -
2010
Young Investigator Award -
2009
Milstein Young Investigator Award -
2008
Presidential Early Career Award for Scientists and Engineers (PECASE) -
2008
Pew Scholar
Specific Clinical/Research Interests: Host-Pathogen Interactions
Current Students: Julie Eggenberger, Rasmus Moeller
Postdoctoral Fellows: Tristan Jordan, Daniel Melo-Blanco, Benjamin Nilsson
Research Personnel: Maryline Panis
Overview:
The tenOever lab is interested in the way cells have evolved to defend themselves against virus. More specifically, the lab focuses on what constitutes different cellular defense systems, how these systems have been shaped over time, and how viruses circumvent them and cause disease.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. tenOever did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.